Insider Monkey
Jim Cramer Says “Chatter” About NVIDIA (NVDA)’s Circular Deals is “Nonsense”
📈
AI Sentiment
Highly Positive
8/10
- Home
- LLY
as of 01-28-2026 3:49pm EST
$1,021.40
$18.11
-1.74%
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Upcoming Earnings Alert:
Get ready for potential market movements as Eli Lilly and Company (LLY) prepares to release earnings report on 04 Feb 2026.
| Founded: | 1876 | Country: | United States |
| Employees: | N/A | City: | INDIANAPOLIS |
| Market Cap: | 950.7B | IPO Year: | N/A |
| Target Price: | $1104.00 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 19 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 20.44 | EPS Growth: | 121.02 |
| 52 Week Low/High: | $623.78 - $1133.95 | Next Earning Date: | 02-04-2026 |
| Revenue: | $59,419,800,000 | Revenue Growth: | 45.41% |
| Revenue Growth (this year): | 42.97% | Revenue Growth (next year): | 21.50% |
AI-Powered LLY Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 77.16%
77.16%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Eli Lilly and Company (LLY)
LILLY ENDOWMENT INC
Sell
10% Owner
LLY Jan 7, 2026
Avg Cost/Share
$1,101.51
Shares
292,148
Total Value
$322,380,730.46
Owned After
92,098,426
LILLY ENDOWMENT INC
Sell
10% Owner
LLY Jan 5, 2026
Avg Cost/Share
$1,085.01
Shares
1,390
Total Value
$1,508,165.29
Owned After
92,098,426
SEC Form 4
LILLY ENDOWMENT INC
Sell
10% Owner
LLY Dec 29, 2025
Avg Cost/Share
$1,085.04
Shares
3,593
Total Value
$3,898,530.76
Owned After
92,098,426
SEC Form 4
LILLY ENDOWMENT INC
Sell
10% Owner
LLY Dec 24, 2025
Avg Cost/Share
$1,085.17
Shares
2,629
Total Value
$2,852,919.82
Owned After
92,098,426
SEC Form 4
LILLY ENDOWMENT INC
Sell
10% Owner
LLY Dec 23, 2025
Avg Cost/Share
$1,085.04
Shares
240
Total Value
$260,409.12
Owned After
92,098,426
SEC Form 4
LILLY ENDOWMENT INC
Sell
10% Owner
LLY Nov 25, 2025
Avg Cost/Share
$1,093.76
Shares
162,693
Total Value
$178,423,264.13
Owned After
92,098,426
LILLY ENDOWMENT INC
Sell
10% Owner
LLY Nov 24, 2025
Avg Cost/Share
$1,070.96
Shares
142,307
Total Value
$152,058,090.84
Owned After
92,098,426
LILLY ENDOWMENT INC
Sell
10% Owner
LLY Nov 21, 2025
Avg Cost/Share
$1,058.46
Shares
105,326
Total Value
$111,504,097.67
Owned After
92,098,426
LILLY ENDOWMENT INC
Sell
10% Owner
LLY Nov 19, 2025
Avg Cost/Share
$1,052.87
Shares
167,526
Total Value
$176,098,702.11
Owned After
92,098,426
LILLY ENDOWMENT INC
Sell
10% Owner
LLY Nov 18, 2025
Avg Cost/Share
$1,035.01
Shares
60,213
Total Value
$62,306,968.56
Owned After
92,098,426
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| LILLY ENDOWMENT INC | LLY | 10% Owner | Jan 7, 2026 | Sell | $1,101.51 | 292,148 | $322,380,730.46 | 92,098,426 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Jan 5, 2026 | Sell | $1,085.01 | 1,390 | $1,508,165.29 | 92,098,426 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Dec 29, 2025 | Sell | $1,085.04 | 3,593 | $3,898,530.76 | 92,098,426 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Dec 24, 2025 | Sell | $1,085.17 | 2,629 | $2,852,919.82 | 92,098,426 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Dec 23, 2025 | Sell | $1,085.04 | 240 | $260,409.12 | 92,098,426 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Nov 25, 2025 | Sell | $1,093.76 | 162,693 | $178,423,264.13 | 92,098,426 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Nov 24, 2025 | Sell | $1,070.96 | 142,307 | $152,058,090.84 | 92,098,426 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Nov 21, 2025 | Sell | $1,058.46 | 105,326 | $111,504,097.67 | 92,098,426 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Nov 19, 2025 | Sell | $1,052.87 | 167,526 | $176,098,702.11 | 92,098,426 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Nov 18, 2025 | Sell | $1,035.01 | 60,213 | $62,306,968.56 | 92,098,426 |
Latest Eli Lilly and Company News
LLY Breaking Stock News: Dive into LLY Ticker-Specific Updates for Smart Investing
Simply Wall St.
Eli Lilly Expands Beyond GLP 1s With Gene Editing And Oncology Bets
📈
AI Sentiment
Highly Positive
8/10
Pharmaceutical Technology
CMS selects next batch of 15 high-cost medicines for third negotiation cycle
➖
AI Sentiment
Neutral
4/10
Reuters
Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless
📈
AI Sentiment
Highly Positive
8/10
GlobeNewswire
Seamless Therapeutics Announces Global Research Collaboration with Lilly to Develop Programmable Recombinase-based Therapeutics for Hearing Loss
📈
AI Sentiment
Highly Positive
9/10
Compare LLY vs Leading Stocks
See how LLY stacks up against similar companies in the market
Head-to-Head Comparisons
More Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "LLY Eli Lilly and Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.